{"id":"W2967569980","doi":"10.1200/jco.19.01492","title":"Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Nivolumab; Adverse effect; Transplantation; Oncology; Lymphoma; Anaplastic large-cell lymphoma; Gastroenterology; Surgery; CD30; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001161781,0.0006221099,0.001154938,0.0001851353,0.0001861894,0.0006587747,0.0005167467,0.0005424881,0.001717793],"category_scores_gemma":[0.000552036,0.0002584274,0.001008596,0.0002052228,0.0003284011,0.0003071354,0.0002045069,0.001273198,0.0003729374],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005434966,"about_ca_system_score_gemma":0.000633276,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007252877,"about_ca_topic_score_gemma":0.001763946,"domain_scores_codex":[0.9997719,0.000120046,0.00001220479,0.00003219247,0.00003197364,0.00003172513],"domain_scores_gemma":[0.999622,0.00006976102,0.00009802546,0.00003182861,0.00003007779,0.0001483439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6510679,0.03721179,0.0228219,0.002296238,0.00441823,0.0004424074,0.0003293872,0.005437421,0.06373275,0.0002687394,0.006047675,0.2059256],"study_design_scores_gemma":[0.5458307,0.3697923,0.06341168,0.000171485,0.002636946,0.0007122188,0.00007510655,0.003234747,0.007726238,0.0001679307,0.00618731,0.00005341422],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938124,0.003828135,0.0002289482,0.0001402262,0.00003806728,0.0004768243,0.0004840743,0.00004908826,0.0009422627],"genre_scores_gemma":[0.9943404,0.002261097,0.0004755772,0.000429997,0.00007605534,0.0003463841,0.00126478,0.00001253043,0.0007931523],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001717793,"threshold_uncertainty_score":0.006144166,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04362826385976647,"score_gpt":0.3842308283635864,"score_spread":0.3406025645038199,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}